populations (19, 20) . CTLs with relative high-or lowaffinity TCR can be elicited in vitro by coculturing the lymphocytes with low or high concentrations of target antigen, respectively (21) (22) (23) . Importantly, the effector function of the resulting CTLs has been shown to correlate with TCR affinity (23) . High-affinity CTLs with specificity for gag, an HIV antigen, were induced to undergo apoptosis when stimulated with high-dose peptide antigen in vitro (22) , suggesting that a high viral load might lead to clonal deletion of high-affinity HIV-specific CTLs over time. Similarly, CD4 + TCR affinity has been shown to be inversely correlated to antigen dose (24) , and in a murine model of CD4 + T cell autoreactivity to myelin basic protein, prevention of autoimmunity was observed after loss of high-affinity T cells and outgrowth of low-affinity T cells during exposure to high doses of antigen (25) . These studies suggest there is a peripheral control mechanism preventing the expansion of high-affinity autoreactive T cells that is similar to the differential avidity model for central tolerance (26, 27) . It is not known whether similar peripheral tolerance mechanisms apply to self-antigens that are also tumor antigens in humans.
In this study, we set out to determine whether we could identify PR1-specific CTLs with both high-and lowaffinity TCR in the peripheral blood of healthy donors and patients with leukemia. We show that there is a selective absence of high-avidity PR1-CTLs in the peripheral blood of untreated CML patients, but that they are readily expanded along with low-affinity PR1-specific CTLs from the peripheral blood of healthy donors and that they are circulating in IFN-sensitive CML patients in cytogenetic remission. Furthermore, we show that effector function of PR1-CTLs correlate with TCR avidity and that high-avidity PR1-CTLs die by apoptosis when exposed to either high-dose peptide antigen or to CML that overexpresses proteinase 3. These results show that specific deletion of peripheral high-avidity CTLs specific for a leukemia-associated self-antigen occurs in CML patients, which may allow outgrowth of leukemia cells that overexpress the antigen.
Methods
Patients and donors. Donors and patients were treated at the University of Texas M.D. Anderson Cancer Center on protocols approved by the Institutional Review Board. After informed consent, cells from the CML patients and their HLA-matched bone marrow (BM) transplantation donors were obtained. PBMCs from untreated CML patients or from patients receiving IFN were collected and cryopreserved for later analysis. Cells were separated using Ficoll-Hypaque gradient-density (Organon Teknika Corp., Durham, North Carolina, USA) and frozen in RPMI-1640 complete medium (CM) (25 mM HEPES buffer, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin; Life Technologies Inc., Gaithersburg, Maryland, USA) supplemented with 20% heat-inactivated pooled human AB serum (AB; Sigma-Aldrich, St. Louis, Missouri, USA) and 10% DMSO, according to standard protocols. Before use, cells were thawed, washed, and suspended in CM plus 10% AB. High-resolution HLA testing was performed by the HLA Laboratory at M.D. Anderson Cancer Center.
Peptide synthesis. PR1 (aa 169-177) peptide (VLQEL-NVTV) was synthesized by Bio-Synthesis (Lewisville, Texas, USA), and the HLA-A2-restricted CMV pp65 peptide (NLVPMVATV) was synthesized by the M.D. Anderson Protein and Nucleic Acid Facility, both to a minimum of 95% purity.
Cell lines and peptide binding. T2 cells (American Type Culture Collection, Rockville, Maryland, USA) were maintained in culture in CM plus 10% FBS (Atlanta Biologicals Inc., Norcross, Georgia, USA). PR1 peptide was incubated at increasing concentrations for 18 hours at 37°C with 100 µg/ml β 2 m (Sigma-Aldrich) with 10 6 T2 cells in 1 ml CM. Cells were washed twice with CM, stained with BB7.2 Ab, washed again, and then stained with FITC-labeled secondary Ab (Becton Dickinson Immunocytometry Systems, San Jose, California, USA). HLA-A*0201 expression was measured by FACS.
Peptide-specific CTLs were expanded in culture using methods described previously (15, 16) . Briefly, PBMCs from healthy donors or CML patients were stimulated in vitro with PR1, pp65, or flu peptides. T2 cells were washed three times in serum-free CM and incubated with peptide at the indicated peptide concentration for 2 hours in CM. The peptide-loaded T2 cells were then irradiated with 7,500 cGy, washed once, and suspended with freshly isolated PBMCs at a 1:1 to a 1:2 ratio in CM supplemented with 10% AB. After 7 days in culture, a second stimulation was performed, and the following day, 60 IU/ml of recombinant human interleukin-2 (rhIL-2) (BioSource International, Camarillo, California, USA) was added. After 14 days in culture, a third stimulation was performed, followed on day 15 by addition of rhIL-2. A fourth stimulation was performed on day 21, followed on day 22 by the addition of rhIL-2. After a total of 27-28 days in culture, the peptide-stimulated T cells were obtained and tested for peptide-specific and leukemia-specific cytotoxicity as well as for phenotypic analyses.
Tetramer synthesis. Production of MHC/peptide tetramers was described in detail elsewhere (13, 14) . Briefly, a 15-amino acid substrate peptide (BSP) for BirA-dependent biotinylation has been engineered onto the COOH terminus of HLA-A2. The A2-BSP fusion protein and human β 2 m were expressed in Escherichia coli and were folded in vitro with the specific peptide ligand. The properly folded MHC-peptide complexes were extensively purified using FPLC and anion exchange and biotinylated on a single lysine within the BSP using the BirA enzyme (Avidity, Denver, Colorado, USA). Tetramers were produced by mixing the biotinylated MHC-peptide complexes with phycoerythrin-conjugated (PE-conjugated) Neutravidin (Molecular Probes Inc., Eugene, Oregon, USA) at a molar ratio of 4:1. PR1 tetramers were validated by staining against a CTL line specific for PR1. CMV tetramers were validated by staining PBMCs from a CMV-immune individual.
Ab's and flow cytometry. For routine surface-antigen staining, 10 6 PBMCs were incubated at 4°C with Ab. After washing, cells were incubated with FITC-labeled CD8 (Caltag Laboratories Inc., Burlingame, California, USA) for 30 minutes on ice. Surface expression of TCR was determined with FITC-labeled TCR-αβ (PharMingen, San Diego, California, USA), and annexin V using FITC-labeled Ab (Caltag Laboratories). Proteinase 3 expression was determined with primary mouse Ab (Accurate Chemical & Scientific Corp., Westbury, New York, USA). Mouse monoclonal anti-HLA-A2.1 Ab BB7.2 and anti-HLA-ABC w6/32 were derived from culture supernatants of a hybridoma cell lines (American Tissue Culture Collection). Cells were washed and fixed in 2% paraformaldehyde and analyzed on a FACScan (Becton Dickinson Immunocytometry Systems), and data were analyzed using CELLQuest (Becton Dickinson Immunocytometry Systems) software. The minimum concentration of tetramer necessary to show distinctly different avidities was determined in titration experiments. Each tetramer reagent was titered individually and used at the optimal concentration. The tetramer concentration showing the maximal separation of fluorescence intensity of CTL populations was generally 10-20 µg/ml. Propidium iodide (PI) (Becton Dickinson Immunocytometry Systems) staining (1 µg/ml) was performed to exclude dead cells, according to the manufacturer's instructions. A "dump" channel was used with tetramer staining to eliminate monocytes and B lymphocytes with nonspecific binding to the HLA-A2 heavy chain by staining with PerCP-labeled CD14 and CD19 (both Becton Dickinson Immunocytometry Systems).
Detailed methodology for detection of t 1/2 of tetramer dissociation was described elsewhere (19) . Briefly, T cells were stained for 45 minutes with PR1/HLA-A2 tetramer, washed, and cooled to 4°C. To prevent rebinding of tetramer, cells were incubated in the presence of PI (1 µg/ml) with saturating amounts of BB7.2 Ab, and flow cytometry was used to measure fluorescence decay at 10-minute intervals. A constant number of CD8 + events was acquired at each time point. Total fluorescence within the tetramer-positive gate was normalized per CD8 + cell, and the antigen-specific fluorescence was determined by subtracting the total fluorescence of control healthy donor lymphocytes from the observed total fluorescence of the lymphocyte populations following peptide stimulation. This antigen-specific fluorescence was normalized to the percentage of the total fluorescence at the initial time point and plotted on a logarithmic scale. Tetramer dissociation t 1/2 was determined by plotting ln (normalized fluorescence) versus time, and is given by t 1/2 = 0.693/k, where k is the slope of the normalized fluorescence decay curve determined by the method of linear least squares.
CTL cytotoxicity assay. A semiautomated minicytotoxicity assay was used to determine specific lysis as described previously (14, 15) . Briefly, effector cells were prepared in doubling dilutions from 6 × 10 3 to 25 × 10 3 cells/well and were plated in 40 µl, 60-well Terasaki trays (Robbins Scientific, Sunnyvale, California, USA) with six replicates per dilution. Target cells (T2 cells, marrow-derived leukemic cells, or BM from a healthy donor) at a concentration of 2 × 10 6 cells/ml were stained with 10 µg/ml of Calcein-AM (Molecular Probes Inc.) for 60 minutes at 37°C. After washing three times in CM plus 10% AB, target cells were resuspended at 10 5 cells/ml, and 10 3 target cells in 10 µl medium were added to each well containing effector cells. Wells with target cells alone and medium alone were used for maximum (max) and minimum (min.) fluorescence emission, respectively. After 4 hours' incubation at 37°C in 5% CO 2 , 5 µl FluoroQuench (One Lambda Inc., Canoga Park, California, USA) was added to each well, and the trays were centrifuged for 1 minute at 60 g before measurement of fluorescence using an automated CytoFluor II plate reader (PerSeptive Biosystems, Framingham, Massachusetts, USA). The percentage of lysis was calculated as follows: % lysis = {1 -[(mean experimental mission -mean min.)/(mean max -mean min.)]} × 100%.
Results

PR1-specific CTLs with high and low TCR avidity can be elicited from healthy donors.
PBMCs from an HLA-A2.1 + healthy donor stimulated weekly for 28 days with 0.2 µM PR1 elicited 1.3% high-intensity PR1/HLA-A2 tetramer-staining CTLs with a median channel of fluorescence (MCF) of 293 (high-avidity PR1-CTLs), while stimulation with 20 µM PR1 produced 3.1% lowavidity (MCF = 93) PR1-specific CTLs ( Figure 1a ). PBMCs stimulated with 2 µM PR1elicited PR1-CTLs with intermediate TCR avidity (MCF = 211). Total TCR-αβ expression was comparable for cells elicited with 0.2, 2.0, or 20 µM PR1, suggesting that differences in tetramer staining were not due to differences in TCR expression level. Cultures stimulated with 2 µM PR1 produced fewer PR1-specific CTLs with mixed TCR avidities, while stimulation with 0.02 µM PR1 induced less than 0.1% PR1-CTLs. The efficiency of eliciting either high-or low-avidity PR1-CTLs was greatest for PBMCs stimulated with either 0.2 µM or 20 µM PR1, respectively. PR1-CTL cell numbers increased up to week 4, and similar results were obtained from PBMCs from two additional HLA-A2.1 + healthy donors (data not shown).
The dose of PR1 peptide that stabilized maximal HLA-A2.1 expression on T2 cells was 200 µM, and HLA-A2.1 expression increased linearly from 2 µM to 200 µM PR1, which was approximately equivalent to the dose range of peptide that induced predominantly high-or low-avidity PR1-specific CTLs, respectively (Figure 1b) . Since the same peptide-loaded T2 cell line was used to induce PR1-specific CTLs, these results indicate that a difference in the density of PR1/HLA-A2 on the APCs affects TCR avidity.
Next, T2 cells were pulsed with increasing doses of PR1 from 0.002 µM to 20 µM and combined with PR1-CTLs elicited with either low (0.2 µM) or high (20 µM) PR1 concentrations. The PR1-CTLs elicited with low PR1 showed higher specific lysis of PR1-pulsed T2 target cells than PR1-CTLs elicited with high PR1 concentration, when both were normalized at an effector-totarget ratio (E/T) of 10:1 based on the total number of PR1/HLA-A2 tetramer-positive events in the CTL cultures (Figure 1c ). This shows that PR1-CTLs expanded with low concentrations of PR1 peptide have a lower threshold of activation than PR1-CTLs expanded with high PR1 concentrations, which is consistent with CTLs bearing higher and lower TCR avidities, respectively.
Since other studies have not shown a correlation of tetramer staining intensity with TCR avidity (28-30), we therefore verified our results by determining the kinetics of tetramer-staining decay using techniques described previously (19) . PR1-CTLs elicited with either low (0.2 µM) or high (20 µM) PR1 concentrations for 4 weeks were incubated with PR1/HLA-A2 tetramer and saturating concentration of BB7.2 anti-HLA-A2 mAb to prevent rebinding. Normalized total fluorescence was measured at 4°C at the appropriate time points and linear tetramer-staining decay plots were obtained, indicating tetramer staining t 1/2 should be proportional to the t 1/2 of the respective TCR-peptide/HLA-A2 complexes (Figure 1d ). PR1-CTLs elicited with low (0.2 µM) PR1 showed a threefold longer t 1/2 than PR1-CTLs elicited with high (20 µM) PR1 (58 min versus 19 min), which correlates with overall high and low tetramer fluorescence (Figure 1a) , respectively, and validates the use of overall tetramer fluorescence intensity to indicate relative TCR avidity.
CML target-cell killing by PR1-specific CTLs correlates with TCR avidity. To evaluate whether CTL lines with different TCR avidities showed differences in effector function, we tested 4-week-old PR1-CTL lines derived from a healthy donor or from patients with CML for the ability to kill HLA-A2 + CML target cells from a patient with blast crisis CML, autologous chronic phase CML cells from patient CML no. 3 at time of diagnosis, or cells from healthy donors. PR1-CTLs derived from the healthy donor with high or low avidity were each combined with either BM from the patient with CML or BM from the patient's healthy HLA-matched sibling in
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The High-avidity PR1-specific CTLs cause more specific lysis of CML BM cells than low-avidity PR1-specific CTLs. After 4 weeks in culture, PR1-stimulated CTLs were coincubated in a 4-hour microcytotoxicity assay with bone marrow cells, and specific lysis was determined. Six replicate wells were used for each dilution of effector cells. Specific lysis is plotted versus E/T ratio, and effector number was normalized for the number of PR1/HLA-A2 tetramer-staining cells in the bulk culture. (a) High-avidity PR1-specific CTLs from a healthy donor showed greater specific lysis of CML target cells than low-avidity PR1-specific CTLs. (b) PR1-specific CTL line from a CML patient 3 months after IFN treatment preferentially lyse autologous BM target cells taken at time of diagnosis over healthy HLA-A2 + BM cells from a third party, and the amount of CML target cell lysis is similar to that produced by healthy donor-derived low-avidity PR1-specific CTLs. Failure to elicit high-avidity CTLs was restricted to PR1, since we could elicit high-avidity p65-specific CTLs from the CMV seropositive patient CML no. 2 using 0.2 µM pp65 peptide-pulsed T2 cells (Figure 3c) .
Because we have shown previously that detection of functional PR1-CTLs in CML patients correlates with a cytogenetic response to IFN-α (14), we hypothesized that low-avidity PR1-CTLs present in high enough number may be capable of reducing the number of leukemia cells in patients that respond to IFN-α, especially after the expansions in cell numbers that we observed. To address this possibility, we studied two CML patients in a cytogenetic remission after 9 months of IFN treatment (CML no. 5 and CML no. 6 with 0% and 85% Ph + cells, respectively), IFN-resistant patients with no cytogenetic remission (CML no. 7 and CML no. 8), and one untreated newly diagnosed patient (CML no. 9) for the presence of PR1-CTLs with high-or low-avidity TCR. High-avidity PR1-CTLs were identified in both patients in a cytogenetic remission, but in none of the IFN-resistant or untreated patients ( Figure 4 ). However, low-avidity PR1-CTLs could be identified in the IFN-resistant patients, but totaled less than 0.1% of CD8 + cells. This suggests that low numbers of high-avidity PR1-CTLs may be sufficient to contribute to cytogenetic remission in IFN-sensitive patients, but leaves unanswered whether high numbers of low avidity PR1-CTLs may contribute to remission.
High PR1 concentration and proteinase 3-overexpressing CML cells induce apoptosis of high-avidity PR1-specific CTLs.
Because high-affinity virus-specific T cells are eliminated by target cells infected with a high viral load (21, 22) , and because CML cells frequently overexpress proteinase 3 (15, 16), we hypothesized that high-avidity PR1-CTLs might be undetectable in untreated CML
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The patients due to selective elimination by CML cells that overexpress the target antigen.
PBMCs from a second HLA-A2 + healthy donor were stimulated with either 0.2 µM or 20 µM PR1-pulsed T2 cells for 28 days to elicit high-or low-avidity PR1-CTL, respectively. Seven days after the last peptide restimulation, we challenged an equal number of CTLs with T2 cells pulsed with either high or low doses of PR1 and then studied them for evidence of apoptosis by annexin V staining 16 to 18 hours later. High-avidity PR1-CTLs underwent apoptosis when challenged with highdose (20 µM) PR1 peptide, but not when challenged with low-dose (0.2 µM) PR1 ( Figure 5 ). All high-avidity PR1-CTLs exposed to high-dose PR1 were dead after 36 to 48 hours of coculture. Apoptosis was abrogated in the presence of the BB7.2 blocking Ab to HLA-A2.1, and no apoptosis was observed when 20 µM of the irrelevant peptide Flu was used instead of PR1. In contrast, low-avidity PR1-CTLs did not undergo apoptosis when challenged with either high-or low-concentrations of PR1 (Figure 5b ).
To determine whether CML cells similarly induced apoptosis of high-avidity PR1-CTL, we performed coincubation experiments with HLA-matched BM cells from CML patients, followed by staining for annexin V 16-18 hours after coincubation. High-avidity PR1-CTLs underwent apoptosis by 18 hours after coculture with BM from an HLA-matched patient with CML in chronic phase with 100% Ph + cells (Figure 6a) . No apoptosis was induced by coincubation with BM cells from an HLA-A2-negative CML patient with 100% Ph + cells or by coincubation with BM cells from an HLA-A2 + healthy donor. In contrast, less than 1% of the low-avidity PR1-CTLs underwent apoptosis when challenged with either the HLA-A2 + or HLA-A2 -CML cells (Figure 6b ). MHC I expression was similar in the two patient samples (Figure 6c) , and similar overexpression of cytoplasmic proteinase 3 was observed in BM cells from each of the CML patients (2.8-fold higher in the HLA-A2 + cells and 3.3-fold higher in the HLA-A2 -cells compared with healthy donor BM cells; Figure 6d ). Therefore, differences in apoptosis were likely due to differences in the amount of PR1 peptide presented on the CML cells.
Discussion
Our study demonstrates that distinct CTLs with relative high or low avidity for the PR1 leukemia-associated self-antigen are present in the peripheral circulation of healthy individuals and that each can be readily expanded in short-term cultures. The high-avidity PR1-CTLs are twofold more potent at killing CML cells than low-avidity PR1-CTLs. Importantly, high-avidity CTLs are selectively deleted by apoptosis after exposure to high PR1 peptide concentrations and after exposure to CML cells that overexpress proteinase 3, which could be blocked by Ab to HLA-A2. Only low-avidity CTLs are detected in the peripheral blood of patients with CML, and we were unable to elicit high-avidity PR1-CTLs from untreated CML patients despite varying culture conditions. Interestingly, high-avidity PR1-CTLs were detected with tetramer staining in unstimulated CML patients that were in a cytogenetic remission after IFN treatment. Together, these data suggest a novel escape mechanism from tumor immunity by leukemiainduced selective deletion of high-avidity effector cells that have the greatest potency against CML. Since we did not detect PR1-CTLs in unstimulated PBMCs from untreated CML patients, it is likely that proteinase 3 antigen overexpression is too low to elicit low-avidity PR1-CTLs in vivo, but it is sufficiently high to induce apoptosis of the high-avidity PR1-CTL. Our results have important implications for tumor immunotherapy strategies. Recent vaccines use peptide or protein tumor-associated self-antigens at fixed milligram-range doses or cellular vaccines that overexpress tumor antigens to elicit immunity, but there has been limited clinical activity; none have produced significant lasting immunity (31, 32) . Methods to improve immunogenicity using heteroclitic peptides or altered peptide ligands with single amino acid modifications that improve MHC binding have been more effective in eliciting T cells specific for tumor-associated self-antigens (31, 33) . However, the increased peptide-MHC binding affinity might also prolong the half-life of peptide/MHC binding to TCR, which might resemble the overexpression of the native antigen. Although the altered peptide ligands might therefore eliminate highaffinity T cells, TCR affinity was not reported in these trials. The therapeutic "window" of antigen concentration presented to T cells may be critically important to stimulate optimal immunity to tumors. In addition to antigen dose, the route of administration, the delivery method (dendritic cells, peptide, protein, or DNA), and the adjuvant used are all likely to influence the eventual T cell repertoire, and future vaccine trials should be optimized for antigen doses that maximize the most potent immunity. This is likely to involve smaller amounts of antigen than is currently being used. Alternatively, adoptive cellular strategies using high-avidity T cells that have been selectively expanded ex vivo may circumvent the problem of optimizing vaccine dosing.
During the course of an immune response to repeated antigenic challenge, TCR with the highest affinity for peptide/MHC can become dominant, due to preferential expansion of cells expressing TCRs, with the slowest dissociation rates for peptide/MHC binding (19) . This has been observed after secondary immunization with a fixed amount of antigen. When a malignant cell overexpressing tumor-associated self-antigens expands, however, high-affinity T cells with specificity for those tumor antigens might be selectively eliminated over time through clonal deletion. This is similar to the process of clonal exhaustion of high-affinity CD8 + T cells that occurs during viral infection (34), which has also been shown for CD4 + cells (24) .
The presence of high-avidity PR1-specific lymphocytes suggests incomplete self-tolerance against proteinase 3 in healthy individuals. The autoimmune disease Wegener's granulomatosis is associated with an antineutrophil cytoplasmic Ab (ANCA) specific for proteinase 3 (35) , and T cells taken from patients with active vasculitic lesions proliferate when exposed to purified proteinase 3 (36) . There are no signs of autoimmunity, however, in any of the healthy donors in this study, nor in any of the CML patients that we have shown previously to have significant numbers of circulating PR1-CTLs (14) , and none were ANCA + . Although the peptides being recognized in Wegener's granulomatosis patients are unknown, T cells from these patients do not proliferate to PR1-pulsed T2 cells (36) . Since the proteinase 3 transcript is not expressed in the thymus (data not shown), peripheral tolerance mechanisms may be most important in shaping the immune response against this protein. This may occur through a gradual shaping of the T cell repertoire toward a low-avidity PR1-CTL population with a highactivation threshold, thereby preventing autoimmunity by CTLs with high-affinity TCR (25, 37) .
An alternative explanation for why we are unable to elicit and detect high-avidity PR1-CTLs in untreated or IFN-resistant CML patients is that they are present below the sensitivity of tetramer staining. In titration experiments, we have determined previously the detection threshold of PR1/HLA-A2 tetramer staining to be 0.01%, which is not sensitive enough to detect very rare populations. However, high-avidity pp65-specific CTLs could be expanded from the CML patients using the same culture conditions that successfully expanded high-avidity PR1-CTLs from healthy donors, suggesting that this is not a limitation of the culture conditions. Moreover, unstimulated high-avidity PR1-CTLs were identified in IFN-sensitive patients in cytogenetic remission, which suggests that an effective immune response against CML may depend upon the expansion of highavidity PR1-CTLs. In the unlikely scenario that highavidity PR1-CTLs are also present in untreated and IFNresistant CML patients, but are merely undetectable, they are not present in sufficient numbers to suppress tumor growth. Finally, cytogenetic remission after treatment with IFN correlates with an expansion of PR1-CTLs (14) , but one of the three patients with a cytogenetic remission in the current study had only lowavidity CTLs. This suggests that if sufficient numbers of low avidity could be elicited, adequate antitumor activity may be possible. In support of this, a recent clinical trial using a very large number of adoptively transferred melanoma-specific T cells (10 10 ) was associated with clinical response, although TCR affinity was not measured (38) . We are currently studying more patients to address this question in leukemia patients.
